Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CycloSam® (153-Sm-DOTMP) in Solid Tumors Metastatic to Bone
NCT06008483Phase 1Terminated
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial in bone cancer, solid tumor and bone metastasis (4 arms). Primary endpoint: Dose Limiting Toxicity Rate at 42 days. Started Apr 2022; status: terminated.
02
Conditions
bone cancersolid tumorbone metastasis
Beyond the preview
Go deeper on NCT06008483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008483.